Individual Approach to Lung Cancer Treatment
Author Information
Author(s): Shigematsu Hisayuki, Toyooka Shinichi, Suzuki Makoto
Primary Institution: Okayama University Graduate School of Medicine and Dentistry
Hypothesis
Different types of EGFR mutations affect tumor response to tyrosine kinase inhibitors in lung cancer.
Conclusion
Identifying the specific type of EGFR mutation in lung cancer can help tailor more effective treatments.
Supporting Evidence
- Different types of EGFR mutations convey different sensitivity to TKIs.
- 22% of tumors had EGFR kinase domain mutations.
- More common mutations were found in women and never smokers.
Takeaway
Doctors need to find out exactly what kind of mutation a lung cancer tumor has to give the best medicine.
Methodology
Analysis of EGFR mutations in a large cohort of non-small-cell lung cancer patients.
Potential Biases
Potential bias in mutation type distribution among different demographics.
Limitations
No data on TKI sensitivity for patients with insertion mutations.
Participant Demographics
22% of tumors had EGFR kinase domain mutations; more common mutations were found in women and never smokers.
Statistical Information
P-Value
<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website